Previous 10 | Next 10 |
2023-08-11 11:23:53 ET Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence . The pharmaceutical company's stock closed last week at $36.10, then fell to a 52-wee...
2023-08-11 08:50:00 ET As conventional investment wisdom has it, it's best to buy low and sell high. However, that only works when you have solid reasons to believe a company's shares will bounce back meaningfully after a decline. Some corporations have uncertain prospects that make the...
2023-08-08 18:12:18 ET BofA Securities has upgraded Axsome Therapeutics ( NASDAQ: AXSM ) to neutral, citing an improved outlook for the company's drug Auvelity for major depressive disorder, or MDD. The investment bank said it was upgrading the stock primarily because Axsome's M...
2023-08-08 09:00:00 ET Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE) , a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that its blockbuster drug candidate, zuranolone, failed to win ...
2023-08-07 18:15:31 ET RBC Capital lowered its rating on Sage Therapeutics to sector perform on Monday, calling the FDA's decision not to approve zuranolone for major depressive disorder, or MDD, a "major setback" for the company. RBC said that while it believes the shares already refle...
2023-08-07 17:39:56 ET Wedbush has downgraded Sage Therapeutics ( NASDAQ: SAGE ) to neutral following the FDA's decision to approve its drug zuranolone for the treatment of post-partum depression but not major depressive disorder, or MDD. The investment bank said it hadn't antic...
2023-08-07 16:41:43 ET Oppenheimer has cut its rating for Sage Therapeutics ( NASDAQ: SAGE ) to perform in the wake of news that the FDA has declined to approve its drug zuranolone for the treatment of major depressive disorder. The investment bank said that it had been "incorre...
2023-08-07 13:28:03 ET Gainers: Nektar Therapeutics ( NKTR ) +87% . Enveric Biosciences ( ENVB ) +47% . Sequans Communications S.A. ( SQNS ) +31% . Tabula Rasa HealthCare ( TRHC ) +31% . Missfresh Limited ( MF ) +29% . Sovos ...
2023-08-07 13:21:04 ET Sage Therapeutics, Inc. (SAGE) Business Update Call August 8, 2023 8:00 PM ET Company Participants Ashley Kaplowitz - Investor Relations Barry Greene - Chief Executive Officer Laura Gault - Chief Medical Officer Chris Benecchi - Chief B...
2023-08-07 12:05:00 ET Summary HSBC planning to shift its global HQ; Office markets saw "heightened uncertainty" in Q2 - JLL. Tyson Foods posts results miss; Campbell Soup to buy Sovos Brands in a $2.7B deal. Jefferies says "recession is almost inevitable". Listen be...
News, Short Squeeze, Breakout and More Instantly...
Sage Therapeutics Inc. Company Name:
SAGE Stock Symbol:
NASDAQ Market:
Sage Therapeutics Inc. Website:
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business ...
2024-06-20 13:15:04 ET Scotiabank analyst issues UNDERPERFORM recommendation for SAGE on June 20, 2024 10:00AM ET. The previous analyst recommendation was Underperform. SAGE was trading at $10.525 at issue of the analyst recommendation. The overall analyst consensus : HO...